Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice.

Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM.

Launch Date/Release: July 2, 2026

Expiration Date: August 31, 2027

FACULTY

Ajai Chari, MD

Professor of Clinical Medicine

University of California, San Francisco

Sagar Lonial, MD, FACP, FASCO

Chair and Professor

Department of Hematology and Medical Oncology

Anne and Bernard Gray Family Chair in Cancer

Chief Medical Officer

Winship Caner Institute | Emory University

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice.

Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM.

Launch Date/Release: July 2, 2026

Expiration Date: August 31, 2027

FACULTY

Ajai Chari, MD

Professor of Clinical Medicine

University of California, San Francisco

Sagar Lonial, MD, FACP, FASCO

Chair and Professor

Department of Hematology and Medical Oncology

Anne and Bernard Gray Family Chair in Cancer

Chief Medical Officer

Winship Caner Institute | Emory University

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice.

Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM.

Launch Date/Release: July 2, 2026

Expiration Date: August 31, 2027

FACULTY

Ajai Chari, MD

Professor of Clinical Medicine

University of California, San Francisco

Sagar Lonial, MD, FACP, FASCO

Chair and Professor

Department of Hematology and Medical Oncology

Anne and Bernard Gray Family Chair in Cancer

Chief Medical Officer

Winship Caner Institute | Emory University

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice.

Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM.

Launch Date/Release: July 2, 2026

Expiration Date: August 31, 2027

FACULTY

Ajai Chari, MD

Professor of Clinical Medicine

University of California, San Francisco

Sagar Lonial, MD, FACP, FASCO

Chair and Professor

Department of Hematology and Medical Oncology

Anne and Bernard Gray Family Chair in Cancer

Chief Medical Officer

Winship Caner Institute | Emory University

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice.

Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM.

Launch Date/Release: July 2, 2026

Expiration Date: August 31, 2027

FACULTY

Ajai Chari, MD

Professor of Clinical Medicine

University of California, San Francisco

Sagar Lonial, MD, FACP, FASCO

Chair and Professor

Department of Hematology and Medical Oncology

Anne and Bernard Gray Family Chair in Cancer

Chief Medical Officer

Winship Caner Institute | Emory University

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additional under investigation, the therapeutic landscape continues to evolve rapidly.

In this educational podcast, Dr. Joseph Mikhael highlights key advances in CAR T-cell therapy for MM. He reviews the most impactful data published or presented in 2025 and offers expert insight into how these emerging findings may shape current and future treatment strategies.

Launch/Release Date: December 17, 2025

Activity Expiration Date: November 30, 2026

FACULTY

Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO

Professor, Clinical Genomics and Therapeutics

Translational Genomics Research Institute (TGen), City of Hope Cancer Center

Chief Medical Officer

International Myeloma Foundation

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Launch/Release Date: December 12, 2025 Activity Expiration Date: November 30, 2026

FACULTY

Angela Weyand, MD

Associate Professor, Pediatrics University of Michigan Medical School Pediatric Medical Director University of Michigan HTC Co-Director, Hematology and Pediatric and Adolescent Gynecology Program Ann Arbor, Michigan

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care.

Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL.

Launch/Release Date: December 10, 2025

Activity Expiration Date: November 30, 2026

FACULTY

Raajit Rampal, MD, PhD

Director, Myeloproliferative Neoplasms Program

Director, Center for Hematologic Malignancies

Memorial Sloan Kettering Cancer Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.